Insilico Nominates Oral CBLB Inhibitor ISM3830
Insilico Medicine today nominated ISM3830, a potential best-in-class, orally available, highly selective CBLB inhibitor with an AI-designed novel scaffold, as a preclinical candidate for multiple advanced tumors. The molecule was generated using Chemistry42's 40+ generative models and ADMET predictor, and shows improved ADME/PK, favorable preclinical safety, robust mouse efficacy including CT26 rechallenge, and publication support in the Journal of Medicinal Chemistry.
Key Points
- 1Generates ISM3830, an orally available, highly selective CBLB inhibitor discovered via Chemistry42 AI platform
- 2Targets intracellular checkpoint CBLB to restore T and NK cell function in resistant tumors
- 3Enables combination therapies and oral dosing with improved ADME/PK and favorable preclinical safety
Scoring Rationale
Moderate novelty with strong credibility from peer-reviewed publications, but limited to preclinical nomination without clinical validation.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
